Aralez pharmaceuticals inc. (ARLZ)
CashFlow / Quarterly
Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating Activities
Net loss

-19,741

-45,767

-24,441

-27,520

-27,477

-

-

-

-

Net (loss) income

-

-

-

-

-

-

-

-

-33,788

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

9,365

8,982

9,042

8,902

8,875

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

1,311

Amortization of debt issuance costs

26

27

26

27

26

25

22

22

15

Change in fair value of contingent consideration

5,085

23,056

4,632

3,594

4,443

-

-

-

-

Payment of contingent consideration

775

-

-

-

-

-

-

-

-

Unrealized foreign currency transaction (gain) loss

-102

12

-57

100

-7

57

8

-119

154

(Gain) loss on sale of fixed assets

-181

6

0

0

266

-

-

-

-

Change in fair value of warrants liability

-

0

0

0

-24

-22

18

-159

-4,581

Share-based compensation expense

1,760

2,610

2,961

2,953

2,824

2,663

2,659

2,633

3,910

Benefit from deferred income taxes

-1,147

-

-

-

-

-2,691

-464

-492

-305

Changes in operating assets and liabilities:
Accounts receivable

27,711

2,345

2,708

1,754

-11,421

9,829

736

-3,750

879

Inventory

-816

1,749

-240

754

-452

-107

-36

429

533

Prepaid expenses and other current assets

-613

363

-846

422

1,302

-2,021

43

-904

1,424

Accounts payable

-13,120

1,497

-2,424

-1,488

17,109

2,272

643

-3,657

460

Accrued expenses and other liabilities

61,048

-

-

-

-5,600

-

-

-

-

Deferred revenue

2,646

-

-

-

-

-

-

-

-

Other assets

571

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

5,046

-117

-8,189

Other liabilities

-

-

-

-

-

-

-252

-3,680

2,844

Net cash provided by operating activities

18,577

-9,595

-15,079

-14,600

10,488

-

-

-

-

Investing activities
Net cash (used in) provided by operating activities

-

-

-

-

-

-

-

-

-41,313

Acquisitions of businesses, net of cash acquired

-

-

-

-

-

175,000

25,000

0

17,887

Purchases of property and equipment

32

120

0

241

1,461

2,152

1,356

259

399

Proceeds from sale of property and equipment

2

-

-

-

-

-

-

-

-

Other

-

0

-1

1

215

-

-

-

-

Net cash used in investing activities

-30

-120

1

281

-1,676

-

-

-

-

Financing activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-18,286

Proceeds from issuance of convertible debt

-

-

-

-

-

200,000

0

0

75,000

Proceeds from issuance of common stock

-

-

-

-

-

0

0

0

75,000

Payment of debt and equity issuance costs

-

-

-

-

-

105

0

0

673

Payment of contingent consideration

3,424

2,204

160

3,852

125

-

-

-

-

Proceeds from exercise of stock options / warrants

56

0

0

0

108

-

-

-

-

Proceeds (payments) related to settlement of stock awards

-

-

-

-

-

-

-

-

700

Net cash used in financing activities

-3,368

-2,204

-160

-3,852

-17

-

-

-

-

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

148,627

Net increase in cash and cash equivalents

15,179

-11,919

-15,238

-18,171

8,795

8,387

-36,673

-20,978

89,028

Effect of change in foreign exchange rates on cash and cash equivalents

-184

80

193

218

-9

23

174

-16

182

Supplemental disclosure of cash flow information:
Income taxes paid

40

1,169

412

1,724

5

-

-

-

-

Interest paid

6,774

6,774

6,700

6,627

4,719

-

-

-

-